Danaher Corporation (DHR)
Will Danaher (DHR) Beat Estimates Again in Its Next Earnings Report?
Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3 of the Best Companies to Own in 2025 and Beyond
#Morningstar #BestStockstoInvestIn #StockInvesting These companies have durable competitive advantages and generate reliable cash flows. 00:00 Introduction 00:46 Danaher DHR 01:36 Paychex PAYX 02:17 Equifax EFX I'm Susan Dziubinski with Morningstar.
Here's Why You Should Avoid Investing in Danaher Stock Right Now
DHR experiences weakness in its operations due to softness in the Life Sciences segment. Rising expenses are added concerns.
Danaher: A Resilient And Solid Company With Growth Potential
Danaher has maintained a net earning margin above 15% since 2017. In 2024 Q3, the company had a 36.36% liabilities-to-assets ratio, the lowest level since 2017. Danaher's largest customers have reduced their excess of COVID-19-related products. So, Danaher expects a further boost in its sales.
Danaher Corporation (DHR) Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)
Danaher Corporation (NYSE:DHR ) Annual Evercore ISI HealthCONx Healthcare Conference December 4, 2024 3:25 PM ET Company Participants Rainer Blair - President and CEO Conference Call Participants Vijay Kumar - Evercore ISI Vijay Kumar Great. Thanks, everyone, for joining us this afternoon.
Danaher (DHR) Reliance on International Sales: What Investors Need to Know
Examine Danaher's (DHR) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Understanding Danaher's Cautiousness
Danaher reported okay Q3 earnings, with "cautiousness" probably being the best adjective to describe the release. The company has finally returned to growth and forward-looking commentary seems positive, but management seems reluctant to put numbers around their optimism. There might be a reason behind the conservativeness, which I explain in this article.
Danaher's Q3 Earnings Boosted By Bioprocessing Order Growth, Analyst Maintain Stock Rating
On Tuesday, Danaher Corp DHR reported third-quarter sales of $5.79 billion, up 3% year-over-year, beating the consensus of $5.59 billion.
Danaher Q3 Earnings Surpass Estimates, Diagnostics Sales Up Y/Y
DHR's third-quarter earnings and sales surpass estimates, benefiting from the solid performance of its Life Sciences and Diagnostics segments.
Stock Markets Taper on High Valuations, Upcoming Election
In two weeks we potentially could see a number of prominent news items which could change the trajectory of stock market enthusiasm.
Danaher Corporation (DHR) Q3 2024 Earnings Call Transcript
Danaher Corporation (NYSE:DHR ) Q3 2024 Earnings Call Transcript October 22, 2024 8:00 AM ET Company Participants John Bedford - VP of IR Rainer Blair - President and CEO Matt McGrew - EVP and CFO Conference Call Participants Tycho Peterson - Jefferies Michael Ryskin - Bank of America Doug Schenkel - Wolfe Research Vijay Kumar - Evercore ISI Scott Davis - Melius Research Puneet Souda - Leerink Partners Dan Leonard - UBS Jack Meehan - Nephron Research Operator My name is Ashley and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to the Danaher Corporation's Third Quarter 2024 Earnings Results Conference Call.
Danaher (DHR) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Danaher (DHR) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
